Compile Data Set for Download or QSAR
Report error Found 53 Enz. Inhib. hit(s) with all data for entry = 12330
TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM50634623(US20240300923, Example 14 | CHEMBL5410702)
Affinity DataIC50: 0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM50634624(US20240300923, Example 21 | CHEMBL5421046)
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM50634621(US20240300923, Example 9 | CHEMBL5428211)
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695950(US20240300923, Example 28 | 2-((1r,4r)-4-(2-(1-hyd...)
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM50634625(US20240300923, Example 22 | CHEMBL5408807)
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695951(US20240300923, Example 29)
Affinity DataIC50: 0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM50634622(US20240300923, Example 12 | CHEMBL5397509)
Affinity DataIC50: 0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695925(US20240300923, Example 3)
Affinity DataIC50: 0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695935(US20240300923, Example 13 | 2-((1R,4r)-4-((R)-2-Hy...)
Affinity DataIC50: 0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695927(US20240300923, Example 5 | 6-Methoxy-N-(1-methyl-2...)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695930(US20240300923, Example 8)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695937(US20240300923, Example 15 | 2-((1R,4r)-4-((R)-2-Hy...)
Affinity DataIC50: 0.900nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695941(US20240300923, Example 19)
Affinity DataIC50: 0.900nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695933(US20240300923, Example 11)
Affinity DataIC50: 0.900nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695938(US20240300923, Example 16)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695940(US20240300923, Example 18)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695952(US20240300923, Example 30)
Affinity DataIC50: 1nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695939(US20240300923, Example 17)
Affinity DataIC50: 1.10nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695923(US20240300923, Example 1)
Affinity DataIC50: 1.10nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695946(US20240300923, Example 24)
Affinity DataIC50: 1.20nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695932(US20240300923, Example 10 | N-(1-(Cyanomethyl)-2-o...)
Affinity DataIC50: 1.40nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695949(US20240300923, Example 27 | 2-((1r,4r)-4-(1H-1,2,3...)
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695947(US20240300923, Example 25)
Affinity DataIC50: 1.70nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695948(US20240300923, Example 26 | 2-((1r,4r)-4-(1H-1,2,4...)
Affinity DataIC50: 2.20nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695926(US20240300923, Example 4 | 6-Methoxy-N-(1-methyl-2...)
Affinity DataIC50: 3.90nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695945(US20240300923, Example 23)
Affinity DataIC50: 5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695942(US20240300923, Example 20)
Affinity DataIC50: 5.60nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695924(US20240300923, Example 2 | 6-Methoxy-N-(1-methyl-2...)
Affinity DataIC50: 10.7nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695928(US20240300923, Example 6 | rel-6-Methoxy-N-(1-meth...)
Affinity DataIC50: 199nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM695929(US20240300923, Example 7)
Affinity DataIC50: 459nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695938(US20240300923, Example 16)
Affinity DataIC50: 1.40E+3nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695940(US20240300923, Example 18)
Affinity DataIC50: 2.40E+3nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695932(US20240300923, Example 10 | N-(1-(Cyanomethyl)-2-o...)
Affinity DataIC50: 2.50E+3nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695937(US20240300923, Example 15 | 2-((1R,4r)-4-((R)-2-Hy...)
Affinity DataIC50: 2.70E+3nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM50634621(US20240300923, Example 9 | CHEMBL5428211)
Affinity DataIC50: 3.30E+3nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695952(US20240300923, Example 30)
Affinity DataIC50: 6.90E+3nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695930(US20240300923, Example 8)
Affinity DataIC50: 7.00E+3nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695951(US20240300923, Example 29)
Affinity DataIC50: 8.40E+3nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695941(US20240300923, Example 19)
Affinity DataIC50: 1.06E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695950(US20240300923, Example 28 | 2-((1r,4r)-4-(2-(1-hyd...)
Affinity DataIC50: 1.06E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695923(US20240300923, Example 1)
Affinity DataIC50: 1.30E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695925(US20240300923, Example 3)
Affinity DataIC50: 1.37E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695926(US20240300923, Example 4 | 6-Methoxy-N-(1-methyl-2...)
Affinity DataIC50: 1.83E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM50634625(US20240300923, Example 22 | CHEMBL5408807)
Affinity DataIC50: 2.62E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695933(US20240300923, Example 11)
Affinity DataIC50: 3.63E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695927(US20240300923, Example 5 | 6-Methoxy-N-(1-methyl-2...)
Affinity DataIC50: 4.00E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695935(US20240300923, Example 13 | 2-((1R,4r)-4-((R)-2-Hy...)
Affinity DataIC50: 5.00E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM50634622(US20240300923, Example 12 | CHEMBL5397509)
Affinity DataIC50: 5.82E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695946(US20240300923, Example 24)
Affinity DataIC50: 8.81E+4nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Astrazeneca

US Patent
LigandPNGBDBM695939(US20240300923, Example 17)
Affinity DataIC50: 1.00E+5nMAssay Description:Potency of IRAK4 Inhibitor Compounds in cKit Enzyme Assay. Evaluation of the effects of the IRAK4 inhibitor compounds on the activity of the human cK...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/8/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 53 total ) | Next | Last >>
Jump to: